Neural transplantation is a promising therapeutic strategy for neurodegenerative diseases and other disorders of the central nervous system (CNS) such as Parkinson and Huntington diseases, multiple sclerosis or stroke. Although cell replacement therapy already went through clinical trials for some of these diseases using fetal human neuroblasts, several significant limitations led to the search for alternative cell sources that would be more suitable for intracerebral transplantation.Taking into account logistical and ethical issues linked to the use of tissue derived from human fetuses, and the immunologically special status of the CNS allowing the occurrence of deleterious immune reactions, neural stem/progenitor cells (NSPCs) appear to be an interesting cell source candidate. In addition to their ability for replacing cell populations lost during the pathological events, NSPCs also display surprising therapeutic effects of neuroprotection and immunomodulation. A better knowledge of the mechanisms involved in these specific characteristics will hopefully lead in the future to a successful use of NSPCs in regenerative medicine for CNS disorders.
Keywords: transplantation, immunomodulation, immune reactions, stem cells, regenerative medicine
Citation: Bonnamain V, Neveu I and Naveilhan P (2012) Neural stem/progenitor cells as promising candidates for regenerative therapy of the central nervous system. Front. Cell. Neurosci. 6:17. doi: 10.3389/fncel.2012.00017
Received: 15 February 2012; Paper pending published: 06 March 2012;
Accepted: 26 March 2012; Published online: 11 April 2012.
Edited by:Afsaneh Gaillard, INSERM, University of Poitiers, France
Reviewed by:Corette Wierenga, Utrecht University, Netherlands
Copyright: © 2012 Bonnamain, Neveu and Naveilhan. This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits noncommercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.
*Correspondence: Philippe Naveilhan, INSERM U643, 30 Boulevard Jean Monnet, 44093 Nantes Cedex 01, France. e-mail: email@example.com